Moderna's (NASDAQ: MRNA) market cap has more than quadrupled since the beginning of this year on hopes that its coronavirus vaccine will protect people from COVID-19. In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Brian Orelli discuss what it takes to justify the current valuation. Ultimately, it may come down to how often we need to take the vaccine.
10 stocks we like better than Moderna
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 24, 2020
Corinne Cardina: TradeSeeker would like to know if Moderna is on our list. Moderna's not on our treatment list but Moderna will be on our COVID-19 vaccine candidate list. Brian, do you have any thoughts on Moderna?
Brian Orelli: I think it's overpriced, but I also thought it was overpriced half a market cap ago. So don't necessarily look at me. Don't go selling because I said so because I was wrong all this time.
Again, I think that whether it's valued properly right now is going to mostly depend on whether you have to be retreated with their vaccine. They have other treatments too but I think those are longer-term plays.
The issue is going to be, is the company going to make $5 billion, $10 billion, and then stop selling the thing? If that's the case, it's hard to justify their market cap. I don't know what it's at right now. The ticker there is MRNA in case anybody wants to know. It's $28 billion market cap right now.
At a five price-to-sales ratio, then that's justifying $6 billion in sales. But the five price-to-sales ratio -- we would want to see that $6 billion going on forever. So that five is a good number for a non-growing biotech company or pharmaceutical company. That's basically justifying $6 billion in sales forever. They could do $10 billion and then not have sales for quite a few years as they build the rest of their pipeline, which is all early stage vaccines.
Corinne Cardina: Yeah, great point.